Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy
JR Burton Jr, J Klarquist, KA Im, S Smyk-Pearson… - Journal of …, 2008 - Elsevier
BACKGROUND/AIMS: The role of HCV-specific CD4+ T cells and regulatory T cells in
influencing the outcome of antiviral therapy is incompletely defined. METHODS: CD4+ IFN-γ
ELISPOT assays (n= 58) and flow cytometric analysis of FoxP3-expressing T regulatory cells
(n= 62) were performed on patients from the Virahep-C study at baseline, during and after
cessation of antiviral therapy. RESULTS: Total HCV-specific IFN-γ CD4+ T cell ELISPOT
responses did not increase with therapy, but rather decreased by 8 weeks and remained …
influencing the outcome of antiviral therapy is incompletely defined. METHODS: CD4+ IFN-γ
ELISPOT assays (n= 58) and flow cytometric analysis of FoxP3-expressing T regulatory cells
(n= 62) were performed on patients from the Virahep-C study at baseline, during and after
cessation of antiviral therapy. RESULTS: Total HCV-specific IFN-γ CD4+ T cell ELISPOT
responses did not increase with therapy, but rather decreased by 8 weeks and remained …